Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19172483 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | April 2025 | July 2025 | Allow | 3 | 0 | 0 | No | No |
| 19075217 | MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 18909566 | DERMAL PATCH AND SYSTEMS, KITS, AND METHODS ASSOCIATED THEREWITH | October 2024 | August 2025 | Allow | 10 | 2 | 0 | No | No |
| 18900544 | METHODS OF INSECT CONTROL FOR AN ANIMAL, PRODUCTS THEREOF AND METHODS FOR THEIR PREPARATION | September 2024 | July 2025 | Allow | 10 | 1 | 0 | No | No |
| 18898561 | ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGEL | September 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18725024 | COMPOSITION AND METHOD OF INDUCING SYSTEMIC ACQUIRED RESISTANCE (SAR) IN PLANTS | June 2024 | March 2026 | Allow | 20 | 1 | 0 | Yes | No |
| 18720721 | EFFECT PIGMENTS HAVING A REFLECTIVE CORE AND SEMICONDUCTOR LAYERS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18732895 | Method of Treating Oxidative Stress in Skin and Compositions Therefor | June 2024 | January 2026 | Allow | 19 | 2 | 1 | Yes | No |
| 18668674 | CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDE | May 2024 | November 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18650542 | FORMULATIONS OF AG10 | April 2024 | September 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18630275 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | April 2024 | December 2025 | Allow | 20 | 2 | 0 | No | No |
| 18621501 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | March 2024 | August 2025 | Allow | 17 | 1 | 1 | No | No |
| 18593225 | MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18445785 | Microdaily EMF Protects Against Oxidative and Inflammatory Damage, and Acute and Late Adverse Effects of EMF Radiation | February 2024 | August 2025 | Allow | 19 | 3 | 0 | Yes | No |
| 18539823 | OPHTHALMIC COMPOSITION | December 2023 | January 2026 | Allow | 25 | 2 | 0 | No | No |
| 18487938 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | October 2023 | February 2026 | Allow | 28 | 1 | 0 | No | No |
| 18474052 | MINOXIDIL ADJUVANT THERAPIES | September 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18467858 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18244628 | PHARMACEUTICAL COMPOSITION | September 2023 | February 2026 | Allow | 30 | 4 | 0 | No | No |
| 18456625 | SKIN CARE COMPOSITION | August 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18233853 | GANCICLOVIR COMPOSITIONS AND RELATED METHODS | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18366907 | Hemp Oil/Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and lnflammation | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18218954 | COMPOSITION AND METHOD OF TREATING CONDITIONS ASSOCIATED WITH EXTRACELLULAR MATRIX DYSFUNCTION BY ADMINISTERING MICRONUTRIENT COMPOSITION | July 2023 | April 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18196617 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | May 2023 | August 2023 | Allow | 3 | 1 | 0 | No | No |
| 18315891 | CELLULOSE SCAFFOLDS DERIVED FROM MACROALGAE, PROCESS FOR THE PREPARATION THEREOF AND USES THEREOF | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18112781 | pH TRIGGERED RELEASE PARTICLE | February 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18110079 | Embossed Effect Pigment and Method of Manufacture of Embossed Effect Pigment | February 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18163818 | EXTENDED RELEASE AMPHETAMINE TABLETS | February 2023 | April 2024 | Allow | 15 | 1 | 0 | No | No |
| 18075863 | TOPICAL MUSCLE RELAXATION COMPOSITIONS AND METHODS | December 2022 | March 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18008191 | ULTRASONIC PREPARATION METHOD OF PROTEIN-DERIVED PEPTIDE-POLYSACCHARIDE NANOPARTICLES LOADED WITH BIOACTIVE COMPONENTS | December 2022 | September 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17928993 | LIQUID OPHTHALMIC COMPOSITION COMPRISING A SPIRULINA PLATENSIS FULL EXTRACT | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17928181 | GINGER WATER COMPOSITION HAVING GINGER EXTRACT AND METHOD FOR MANUFACTURING THE SAME | November 2022 | June 2023 | Allow | 6 | 0 | 0 | No | No |
| 18000019 | ANTIVIRAL AGENT FOR PREVENTING OR TREATING COVID-19 | November 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17926940 | EDIBLE FUNGI | November 2022 | September 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18055940 | OPHTHALMIC COMPOSITION | November 2022 | August 2023 | Allow | 9 | 1 | 0 | No | No |
| 18055949 | OPHTHALMIC COMPOSITION | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
| 18055945 | OPHTHALMIC COMPOSITION | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
| 17946621 | IMPLANTABLE MEDICAL DEVICES FOR EXTENDED RELEASE OF THERAPEUTIC AGENTS | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17896474 | ADHESION-PREVENTING COMPOSITION | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17890122 | Shear-Thinning Cosmetic Composition | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17820003 | SETTABLE SURGICAL IMPLANTS AND THEIR PACKAGING | August 2022 | May 2025 | Allow | 33 | 2 | 0 | No | No |
| 17819159 | TOPICAL SKIN TREATMENT COMPOSITION | August 2022 | July 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17879797 | ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND HEALING | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17875236 | FOAMING CLEANSER | July 2022 | July 2024 | Allow | 23 | 3 | 0 | Yes | No |
| 17794178 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACID | July 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17794072 | Alginate Based Particles as a Temporary Embolic Agent | July 2022 | April 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17793640 | TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION | July 2022 | September 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17861658 | BIOLOGICAL PESTICIDE FUNGUS EFFECTIVE AGAINST MULTIPLE DIFFERENT SPECIES OF INSECT | July 2022 | June 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17841284 | GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS | June 2022 | December 2023 | Allow | 18 | 1 | 0 | No | No |
| 17830039 | METHOD AND COMPOSITION FOR REJUVENATION OF MUSCLE CELLS | June 2022 | April 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17780789 | COMPOSITIONS AND METHODS FOR BIOREMEDIATION OF GLYPHOSATE CONTAINING SUBSTRATES | May 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17742960 | DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME | May 2022 | January 2023 | Allow | 8 | 1 | 0 | No | No |
| 17773635 | TEBUCONAZOLE FORMULATIONS | May 2022 | October 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17772728 | ANTI-AGING CHINESE HERB EXTRACT,EXTRACTION METHOD AND USE THEREOF | April 2022 | March 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17659185 | SUPPLEMENT FOR MITIGATING WOMAN'S DISORDERS CAUSED BY AGEING | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | No |
| 17754891 | METHOD FOR PREPARING AN INVERSE EMULSION COMPRISING TWO CATIONIC POLYMERS | April 2022 | February 2023 | Allow | 10 | 0 | 0 | No | No |
| 17767194 | METHOD OF PREPARING A COSMETIC COMPONENT | April 2022 | June 2024 | Allow | 27 | 0 | 0 | No | No |
| 17707507 | Personalized Nutritional Supplements and Methods of Making | March 2022 | February 2024 | Allow | 23 | 5 | 0 | Yes | No |
| 17763404 | COMPOSITION OF A RHEOLOGY MODIFIER AND DIHALOHYDANTOIN | March 2022 | October 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17699200 | CURCUMIN COMPOUND COMPOSITION AND METHOD FOR PREPARAING SAME | March 2022 | September 2025 | Abandon | 42 | 0 | 2 | No | No |
| 17655470 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | March 2022 | June 2023 | Allow | 15 | 1 | 0 | No | No |
| 17689856 | METHOD AND USE OF COMPOSITIONS COMPRISING LIGNOSULFONATE FOR ATTENUATION OF SARS-CoV-2 VIRUS REPLICATION | March 2022 | July 2025 | Allow | 40 | 2 | 1 | No | No |
| 17640451 | USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANA | March 2022 | April 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17685666 | FOOD SUPPLEMENT FOR ORAL ADMINISTRATION | March 2022 | May 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17681640 | SOLUBLE LIQUID COMPOSITIONS OF SAFLUFENACIL, METHOD OF PREPARATION AND USE THEREOF | February 2022 | October 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17678178 | CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDE | February 2022 | September 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17669442 | SHAPE MEMORY ADHESIVE MATERIALS FOR DIABETIC WOUND HEALING | February 2022 | August 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17669136 | Composition and Method Containing Pea and Quinoa Natural Peptides And Niacinamide to Enhance Skin Glow, Radiance And Even Skin Tone | February 2022 | October 2025 | Abandon | 44 | 4 | 1 | Yes | No |
| 17586414 | COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI | January 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17582237 | SKIN CARE SERUM CONTAINING SODIUM HYALURONATE | January 2022 | April 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17627926 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, CONTAINING BENTONITE AS ACTIVE INGREDIENT | January 2022 | June 2024 | Abandon | 29 | 5 | 0 | No | No |
| 17577479 | FORMULATIONS OF AG10 | January 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
| 17576114 | EXTENDED RELEASE AMPHETAMINE TABLETS | January 2022 | June 2025 | Allow | 41 | 2 | 0 | No | No |
| 17559580 | METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING | December 2021 | October 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17559068 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | December 2021 | August 2024 | Allow | 32 | 2 | 0 | No | No |
| 17622082 | PINE OIL-BASED HERBICIDE | December 2021 | February 2026 | Allow | 50 | 2 | 1 | No | No |
| 17556896 | INTERNAL TEAT SEALANTS AND THEIR USE IN THE PREVENTION OF BOVINE MASTITIS IN THE DRY COWB | December 2021 | August 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17620215 | COMPOSITION AND METHOD FOR IMPROVING PLANT GROWTH | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17618888 | LIQUID FORMULATION TO TREAT A CORNEAL TISSUE | December 2021 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17549943 | POLYACRYLONITRILE BASED ELECTROSPUN NANOFIBERS LOADED WITH ZINC OXIDE- QUERCETIN NANOPARTICLES FOR WOUND HEALING | December 2021 | September 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17549980 | Method of Treating Oxidative Stress in Skin and Compositions Therefor | December 2021 | February 2024 | Allow | 26 | 2 | 1 | No | No |
| 17545178 | THERAPEUTIC SYSTEMS, DEVICES, AND COMPOSITIONS WITH WOUND HEALING AND TISSUE REGENERATIVE PROPERTIES, USES THEREOF, AND CORRESPONDING METHODS | December 2021 | January 2024 | Allow | 25 | 5 | 1 | Yes | No |
| 17613390 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING CITRATE AND CARNITINE | November 2021 | February 2026 | Allow | 50 | 3 | 0 | No | No |
| 17530027 | COMPOSITIONS OF MIDODRINE AND METHODS OF USING THE SAME | November 2021 | December 2023 | Allow | 25 | 1 | 1 | No | No |
| 17527377 | OILY SOLID COSMETIC, METHOD FOR PRODUCING THE OILY SOLID COSMETIC, AND METHOD FOR PRODUCING MOLDED PRODUCT USING THE OILY SOLID COSMETIC | November 2021 | December 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17610500 | MICROPARTICLE COMPOSITIONS COMPRISING SAFLUFENACIL | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17609955 | HERBICIDAL COMPOSITION | November 2021 | June 2024 | Allow | 32 | 0 | 0 | No | No |
| 17606402 | COMPOUND COMPRISING A FUNCTIONAL AGENT, AND RELATED MANUFACTURING METHOD | October 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17508908 | Herbicide Compatibility Improvement | October 2021 | July 2025 | Allow | 44 | 0 | 2 | No | No |
| 17605104 | COMBINATION OF MODIFIED STARCH/C13-C15 FATTY ACID/CLAY | October 2021 | September 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17504087 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | October 2021 | December 2023 | Allow | 26 | 1 | 1 | No | No |
| 17602822 | STABILIZATION OF SUSPENSION CONCENTRATES BY ETHOXYLATED RICINOLEIN | October 2021 | August 2025 | Allow | 46 | 1 | 1 | No | No |
| 17600913 | TWO-COMPONENT SYSTEM FOR THE THERAPEUTIC TREATMENT OF SKIN LESIONS AND PRODUCTION METHOD THEREOF | October 2021 | January 2026 | Allow | 51 | 3 | 1 | No | No |
| 17600678 | Antifungal Compositions | October 2021 | July 2025 | Allow | 45 | 3 | 1 | No | No |
| 17474322 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | September 2021 | January 2024 | Allow | 28 | 2 | 0 | No | No |
| 17433906 | COATING COMPOSITION FOR SEED | August 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17401777 | HYPOCHLOROUS ACID-BASED EYELID CLEANSERS | August 2021 | August 2023 | Allow | 24 | 2 | 0 | No | No |
| 17389917 | METHODS OF DYEING KERATIN FIBERS WITH A PIGMENT DYEING COMPOSITION | July 2021 | July 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17427082 | COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING GROWTH FACTOR | July 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17384227 | COLON CLEANSING COMPOSITIONS AND METHOD OF USE | July 2021 | May 2024 | Allow | 33 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JUSTICE, GINA CHIEUN YU.
With a 19.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JUSTICE, GINA CHIEUN YU works in Art Unit 1617 and has examined 1,100 patent applications in our dataset. With an allowance rate of 50.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner JUSTICE, GINA CHIEUN YU's allowance rate of 50.4% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JUSTICE, GINA CHIEUN YU receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JUSTICE, GINA CHIEUN YU is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -5.7% benefit to allowance rate for applications examined by JUSTICE, GINA CHIEUN YU. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 16.3% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 87.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 58.0% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 68.7% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.